Requip (ropinirole), the SECOND new drug for Parkinson's to hit the market

    SmithKline Beecham is now marketing Requip (ropinirole), the SECOND new drug for Parkinson's to hit the market this year.

    The first one, Mirapex (pramipexole) was approved in July.

    Requip and Mirapex are second-generation dopamine agonists.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote